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Abstract 
Aims 
Mesenchymal stem cells (MSC) have recently attracted interest as a potential basis for a cell 
based therapy of AD. We investigated the putative immune-modulatory effects in 
neuroinflammation of systemic transplantation of MSC into APP/PS1 transgenic mice.  
Methods 
106 MSC were injected into APP/PS1 mice via the tail vein and histological analysis was 
performed for microglia and amyloid (pE3-Aβ) plaque numbers, glial distribution and pE3-Aβ 
plaque size. In addition, a biochemical analysis by qPCR for pro-inflammatory, 
chemoattractant and neurotrophic factors was performed. 
Results 
MSC co-localized with pE3-Aβ plaques. The effects of transplantation on microglia-
associated pathology could be observed after 28 hours. Animals showed a reduction in 
microglial numbers in the cortex and in size. Gene expression was reduced for TNF-α, IL-6, 
MCP-1, and for NGF, in MSC recipients. Also, we investigated for the first time and found no 
changes in expression of IL-10, CCR5, BDNF, VEGF and IFNγ. PTGER2 expression levels 
were increased in the hippocampus but were reduced in the cortex of MSC recipients. While 
there were no transplant-related changes in pE3-Aβ plaque numbers, a reduction in the size 
of pE3-Aβ plaques was observed in the hippocampus of transplant recipients. 
Conclusion 
This is the first study to show reduction in pE3-Aβ plaque size. pE3-Aβ plaques have gained 
attention as potential key participants in AD due to their increased aggregation propensity, 
the possibility for the initial seeding event, resistance against degradation and neurotoxicity. 
These findings support the hypothesis that MSC-transplants may affect AD pathology via an 
immune modulatory function that includes an effect on microglial cells. 
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Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease marked histopathologically by 
amyloid β aggregations, neurofibrillary tangles, and neuronal impairment finally leading to 
memory impairments (1). Some reports suggest the role of oxidative and inflammatory stress 
together with microglia changes preceding the onset of clinical and pathological AD 
symptoms (2-5). 
Mesenchymal stem cells (MSC) have recently attracted interest as a potential basis for a cell 
based Alzheimer therapy (6-8) but apart from their clinical potential their mechanism of 
action has yet to be ascertained.  
One potential approach is to study the impact of MSC on microglia, the resident 
macrophages of the brain. Microglia show early signs of dysfunction in AD (9). The microglia 
can either be neuroprotective or neurotoxic depending on the secretion profile and surface 
marker expression (10, 11). Activated microglia secrete a variety of pro-inflammatory 
cytokines including interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-α), which induce 
neuroinflammation (12). Microglia also participate in the recruitment of cells into the brain 
and to AD associated amyloid plaques through chemokine secretion, such as monocyte 
chemotactic protein-1 (MCP-1) (13-15). However, microglia are also known to produce 
neurotrophic factors such as brain-derived neurotrophic factor (BDNF), neuronal growth 
factor (NGF) and vascular endothelial growth factor (VEGF/A), providing trophic support to 
neurons.  
Previous studies in AD mice have been performed using intracranial application of MSC. 
These studies showed promising results however they had several drawbacks including the 
use of human cells in an animal model and an invasive intra-cerebral transplantation delivery 
method (16, 17). There have at present been no studies using systemic MSC injections. One 
study used systemic injections, however the cells used were described as bone marrow 
derived cells and not described or characterised as MSC. Additionally, in the same study the 
animals were also irradiated (18).  
In summary this demonstrated the need for a study that systemically applied MSC via 
injections to an AD mouse model. Also for translational purposes we were interested in 
testing a minimally invasive method of cell administration using systemic injection.  
We found that MSCs were able to migrate into the brain and reduced the amount of middle 
sized pE3-Aβ amyloid plaques. Microglial numbers were not changed, however, we found 
that microglia and astrocyte activation levels were decreased. In addition, the expression of 
several important inflammatory markers were reduced in AD mice transplanted with MSC in 
comparison to control animals. 
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Material and methods  
Animals 
Transgenic mice overexpressing human amyloid precursor protein (APPKM670/671NL) and 
presenilin-1 (PS1L166P) under Thy-1 promoter control (age 12-15 months) were obtained from 
University of Leipzig (Prof. Bechmann) and the German Centre for Neurodegenerative 
Diseases (Prof. M. Jucker,) Tübingen (19). C57BL/6 from the MEZ of the University of 
Leipzig or Charles River were used as a source for bone marrow derived MSC. GFP-
transgenic mice (12 weeks) were from the Paul Flechsig Brain Research Institute, University 
of Leipzig. The experiments were approved by the local Animal Welfare Committee of the 
University of Leipzig and by the local governmental authorities (Landesdirektion Sachsen, 
permit numbers T70/12, T72/13, TVV 07/08). 
MSC preparation 
Bone marrow was cultured in DMEM low glucose (Gibco, 21885-108) with 10% fetal calf 
serum (Hyclone, SV30160.03) and 1% penicillin / streptomycin (Gibco, 15070-063). Briefly, 
mouse bone marrow cells were obtained centrifugally from tibiae and femurae and cultured 
according to the methods of Dobson et al. (20). MSC were isolated by the methods of Sekiya 
et al. (21). MSC were passaged when they were 70% confluent using trypsin (Trypsin-EDTA 
0.25% Gibco). Identity was confirmed by staining for MSC specific markers (CD11-, CD45-, 
CD44+, CD90+, CD105+, CD133+, CD146+, sca-1+) and mesodermal lineage differentiation 
(data see supplement). MSC were used for transplantations at passage 1-2. 
Mesodermal lineage differentiation 
Murine BM-MSC were analysed for their differentiation potential at passage 3. 
Osteogenic differentiation: Cells were seeded at 1x104 cells/1.9 cm2 (24 well-plate, 
GreinerBioOne, 662160) and cultured with osteogenic medium (DMEM low glucose (Gibco, 
21885-108); 10% FBS (Hyclone, SV30160.03); 1% Pencillium/Strepromycin (Gibco, 15070-
063); 10 nM dexamethasone (Sigma-Aldrich, D4902); 50 µg/ml ascorbic acid 2-phosphate 
(Sigma-Aldrich, A8960-5G). Medium was changed every 2 days. After 14 days qualitative 
analysis was done: Cells were fixed with 70% Ethanol (VWR445363) and stained for alkaline 
phosphatase with Fast Red (0.2 M Tris (Sigma-Aldrich 459836); 1 mg/ml Fast Red (Sigma-
Aldrich 51503); 50 μg/ml naphtol phosphate AS-BI (Sigma-Aldrich) for 1 hour. 
Adipogenic differentiation: Cells were seeded at 2x104 cells / 1.9 cm2 (24 well-plate, 
GreinerBioOne, 662160) and cultured with for 7 days with a 1:1 mixture of culture medium 
(DMEM high glucose (Gibco, 31966-047); 1% Pencillium/Streptomycin (Gibco, 15070-063); 
10% FBS (Hyclone, SV30160.03)) and adipogenic medium (culture medium with additionally 
10% insulin-transferrin-selenium supplement, (Sigma-Aldrich, I3146-5ML) 10 nM 
dexamethasone (Sigma-Aldrich, D4902); 0.5 mM isobutylmethylxanthine (Sigma-Aldrich, 
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I7018); 100 μM indomethacin (Sigma-Aldrich, I7378-10G)). After 7 days cells were culture 
only in adipogenic medium. Medium was changed every 2-3 days. After 14 days qualitative 
analysis was done: Cells were fixed with 4% buffered PFA (Thermo Fisher, 28908) and 
stained with 0.45% Oil Red O (Sigma-Aldrich, O0625) in isopropanol (Applichem).  
Chondrogenic differentiation: Cells were seeded at 5x104 cells / 3.9 cm2 (12 well-plate, 
GreinerBioOne, 662180) and cultured with osteogenic medium (DMEM high glucose (Gibco, 
31966-047); 10% FBS (Hyclone, SV30160.03); 1% Pencillium/Strepromycin (Gibco, 15070-
063); 100 nM dexamethasone (Sigma-Aldrich, D4902), 150 μM ascorbic-2-phosphate 
(Sigma-Aldrich, A8960-5G), 20 μM linoic acid (Sigma-Aldrich, L1012) and 10 ng/ml TGF-β 
(Invitrogen, PHG9214). Medium was changed every 2-3 days. After 14 days qualitative 
analysis was done: Cells were fixed with 4% buffered PFA (Thermo Fisher, 28908) and 
stained with Alcian blue under acidic conditions (pH 2.5). 
MSC phenotyping 
Murine BM-MSC were analysed for their CD phenotype at passage 1. Cells were harvested 
by trypsinization and stained with the following antibodies: IgG-FITC (Serotec STAR70, 
1:200), CD11b-FITC (Abcam ab99671, 1:50), CD44-Alexa 488 (Biolegend 103015, 1:50), 
CD45-FITC (Biotec 1660-02S, 1:50), CD90-FITC (1:100; 4°C; 30min; Serotec), CD105-
Alexa 488 (Biozol 120405, 1:50), CD133-FITC (Abcam ab97022, 1:200), CD146 (BD 
Bioscience 553336, 1:50) and sca-1 (BD Bioscience 562196, 1:50) DiI and DiO (Molecular 
Probes/Fischer, 3µl/ml)). MSC were then analysed using the personal flow cytometry system 
(Beckman Coulter). 
Transplantation 
For histological analysis 106 MSC in 150 µl NaCl from female/male donors were injected per 
male animal (day 7 n=3 and day 28 n=4) via the tail vein and for biochemistry analysis 106 
MSC in 150 µl NaCl from male donors were injected into female recipients (day 28, n=3). 
The control mice were injected with 150 µl NaCl (n=11). After 7 or 28 days animals were 
sacrificed and the organs isolated for biochemical or histological analysis. In some cases we 
used MSC from eGFP transgenic mice.  
Tissue preparation 
Mice were perfused 7 and 28 days after transplantation. For biochemistry, mice were 
perfused transcardially after death with 0.9% NaCl. Brains were removed, divided into 5 
regions (hippocampus, cortex, cerebellum, brain stem and olfactory bulb) and stored in 
peqGOLD TriFast™ (PeqLab, 30-2040) at 80°C until further use as well as the pieces of 9 
peripheral organs. 
For histology, mice were perfused transcardially after death with 0.9%NaCl followed by 
fixative containing 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1M phosphate buffer 
(pH7.4). Brains were removed and immersion-fixed overnight in the same fixative at 4°C. 
Brains were cryoprotected in 30% sucrose in 0.1M phosphate buffer (pH7.4) with 0.1% 
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sodium acid, cut into 40µm slices with a cryomicrotome in frontal plane, slices were collected 
in 0.1M phosphate buffer (pH7.4) with 0.1% sodium acid. 
Immunohistochemistry 
Histochemistry was performed with free-floating sections. Brain slices were washed once 
with PBS containing 0.05% Tween20 (Sigma-Aldrich, P2287-100ML) (PBS-T). All washing 
steps were performed 3 times for 5 minutes in PBS-T. Quenching of endogenous peroxidase 
enzyme activity was performed by using 2% H2O2 (VWR Prolabo, 23622.298) in 60% 
methanol (VWR Prolabo, BDH1135) for 60min for staining with 3,3’-Diaminobenzidine (DAB, 
Roth, CN75.1). Sections were incubated in blocking solution consisting of PBS-T plus 2% 
bovine serum albumin (Serva, 11930), 0.3% milk powder (Roth, T145), and 0.5% donkey 
normal serum (Jackson Immuno Research, 017-000-001) for 30 min prior to incubation with 
the primary antibody.  
All slices used were incubated overnight at 4°C in blocking solution and primary antibody. 
The primary antibodies used were: anti-Iba-1 (rabbit, 1:600; Wako), anti-pyroglutamate-beta 
amyloid (pE3-Aβ) (mouse, 1:500; Synaptic Systems) and anti-GFAP antibody (rabbit, 1:700; 
DAKO). After washing 3 times in PBS-T, the biotinylated secondary donkey-anti-mouse IgG 
antibody (1:1000; Dianova) or donkey-anti-rabbit IgG antibody (1:1000; Dianova) was 
applied for 1h in solution containing 50% blocking solution and 50% PBS-T. Sections were 
washed 3 times in PBS-T and incubated in peroxidase-coupled extravidin (1:2000, Sigma-
Aldrich, E2886) for 1h in 1 part blocking solution and 2 parts PBS-T, followed by washing 
and incubation with 0.05M Tris-buffer pH 8 for 5min. Subsequently, brains were placed in 
10ml 0.05M Tris-buffer (pH 8), 4mg DAB and 5µl 30% H2O2 until a colour change was 
visible. For pE3-Aβ staining diaminobenzidine with nickel ammonium sulfate (Sigma-Aldrich, 
7785-20-8) enhancement (DABNi) was used. A solution of 10ml Tris-buffer with 40mg of 
nickel ammonium sulphate was prepared followed by the addition of 4mg DAB. After that 5µl 
30% H2O2 was added to the mixture. Brain slices were incubated in DABNi for 30min. 
Sections were finally washed, placed on glass slides, dried and mounted with entellan in 
toluol (Merck, 108323). 
Immunofluorescence for microglia was carried out with rabbit anti Iba-1 (WAKO, 1:500, 019-
19741) overnight, followed by secondary antibody donkey-anti-rabbit Cy3 (Dianova, 1:250, 
711-165-152) for one hour. Slices for LSM double fluorescence images (Fig. 1) were stained 
without immunohistochemical enhancement for immigrated eGFP+ MSC. 
Immunohistochemistry for astrocytes was performed as followed: brain slices were mounted 
on the cover slides. Autofluorescence quenching was performed by incubating the brain 
slices with Image-IT (Life Technology, I36933) for 30 minutes. After that, brain slides were 
washed twice with PBS followed by incubation with blocking solution for 30 minutes. Then, 
rabbit anti-GFAP antibody (1:700; DAKO, Z033429-2) in blocking solution was added to the 
brain slices and incubated over night at 4°C. Next, brain slices were washed 3 times with 
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PBS and incubated with donkey anti-rabbit Northern Lite 557 (1:200; R&D, NL004) for 1 hr 
followed by washing 3 times with PBS. The nucleus was stained with 0.5µM Sytox Green 
(Life Technology, S7020) for 30 minutes. Brain slices were mounted using ProLong® Gold 
Antifade mounting medium (Molecular Probes, P36934). Immunofluorescence for microglia 
was carried out with rabbit anti Iba-1 (WAKO, 1:300-500, 019-19741) overnight, followed by 
secondary antibody donkey-anti-rabbit Cy3 (Dianova, 1:250, 711-165-152) for one hour. 
Immunofluorescence for GFP was carried out with goat anti GFP overnight, followed by 
secondary antibody donkey-anti-goat Cy2 (Dianova, 1:250, 705-225-147) for one hour. 
Thioflavin S staining 
Floating brain slices were incubated in 0.5% Thioflavin S solution (Sigma, T1892-25G) for 
5min at room temperature. Sections were then washed with 70% ethanol followed by 50% 
ethanol. Each washing step was performed at room temperature for 5min. After the ethanol 
washes, the sections were washed once with water for 5min at room temperature. Sections 
were placed on glass slides, dried and mounted with entellan (VWR, 1079600500). 
Microscopy and image processing 
Tissue sections were examined with the Keyence BZ-9000 microscope equipped with a BZ-
9000 Analyser software (Keyence Corporation, USA) for light and fluorescence microscopy. 
Haze reduction and white/black balance were used to process the images with minimal 
alterations to the brightness, sharpness, colour saturation and contrast. Fluorescence 
labelling (Fig.1) was examined with a Zeiss confocal laser scanning microscope (LSM 510, 
Zeiss, Jena, Germany). For secondary Cy2-labelling (green fluorescence), an argon laser 
with 488-nm excitation was used and emission from Cy2 was recorded at 510-nm applying a 
low-range band pass (505–550 nm). For secondary Cy3-labelling (red fluorescence), a 
helium–neon laser with 543-nm excitation was used and emission from Cy3 at 570 nm was 
detected applying a high-range band pass (560–615 nm). Photoshop CS2 (Adobe Systems, 
Mountain View, CA, USA) was used to process the images with minimal alterations to the 
brightness, sharpness, colour saturation and contrast. 
Stereology 
Microglia (Iba-1) and plaque (pE3-Aβ) numbers were evaluated for the whole cortex and 
hippocampus using Zeiss Axio Imager microscope (Carl Zeiss) and quantified by Stereo 
Investigator 8 software (MBF Bioscience). The distance between each counting frame was 
350µm x 350µm and a counting frame of 250µm x 250µm was used for counting microglia 
and plaque numbers with 20x objective. Where the results were unclear a higher 
magnification (40x or 63x) was used to distinguish cells residing below another. 
Nine sections per animal, taken from beginning to the end of the cortex and hippocampus 
were examined, at a serial interval of every 10 slices, with a counting frame for the cortex 
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~200 and hippocampus ~70 per slice. The whole left cortex and hippocampus were counted 
and the numbers multiplied by 2 to cover both hemispheres. 
Measurement of pyroglutamate-beta amyloid (pE3-Aβ) plaque size 
To determine the amyloid plaque size, pictures from the cortex (4-5 pictures) and 
hippocampus (3-4 pictures) were randomly taken from one slide of each animal. Analysis 
was performed in the anterior, middle and posterior hippocampus and cortex. Photos were 
taken at 20x objective with BZ-9000 Keyence microscope and analysis performed with BZ-II 
Analyser Software (Keyence). Plaque diameter was determined by measuring the distance 
between two opposite points at the plaque edge. A line was drawn from the beginning to the 
end of the plaque and diameter in µm was obtained for each plaque. The software 
automatically calculated the diameter based on the length of the drawn line. 
Microglia covered area measurement  
Microglia covered area was determined using Keyence BZ900 microscope and BZ-II 
Analyser Software (Keyence). Pictures of Iba-1 positive cells (microglia) were taken 
randomly in the cortex (5 pictures) and hippocampus (4 pictures) for every mouse. Analysis 
was performed using the Hybrid Cell Count software module in BZ-II Analyser Software. 
Settings for brightness and threshold were adapted and applied for all measurements. 
Brightness of Iba-1 fluorescence was manually set at a maximum threshold where 
background was barely present. Threshold was established independently for each mouse.  
Areas located on corners and holes were manually excluded to reduce noise in the analysis. 
After setting the brightness parameters Iba-1+ covered area was obtained for every picture. 
Covered area was calculated as the mean of all images determined for every mouse. 
Astrocyte covered area measurement 
Analysis of the total area covered by astrocytes labelled with GFAP antibody was performed 
in the cortex and hippocampus. Single pictures of the whole brain area were taken at 4x 
magnification and merged using BZII Analyser Software. Then, the regions of interest were 
cut out and analysed using the Hybrid Cell Count of the BZII Analyser Software. Settings of 
brightness and threshold were adapted and applied for all measurements. The threshold 
was set to identify astrocyte clusters. To determine the covered area as a whole, the picture 
was re-analysed with the threshold reduced to a minimum to include the whole area.  
RNA isolation and quantitative RT–PCR  
Total RNA was extracted from hippocampus and cortex using peqGOLDTrifastTM reagent 
according to the manufacturer´s instructions (PeqLab, 30-2040). It was treated with DNaseI 
(Life Technologies, EN0521) to remove genomic DNA contamination. This procedure was 
followed by cDNA synthesis using SuperscriptIII-reverse transcriptase (Life Technologies, 
18080085) and Oligo (dT)18-Primers (Thermo Scientific, SO132) at 50°C for 1h. cDNA was 
used as PCR template in a 1:10 dilution and each sample run in triplicate. Quantitative PCR 
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was performed using Express SYBR GreenER qPCR Supermix Universal (Life technologies, 
1178401K), additional 1x SybrGreen (Life technologies, S-7567) and 0.2µM primer each on 
the DNA engine Opticon2 (Biorad) (primers see supplement table 1) with the following cycle 
conditions: primary denaturation at 95°C for 3min, 35 cycles with 30s at 95°C, 30s at 60°C 
and 30s at 72°C followed by fluorescence measurement. Absolute quantification was 
performed for every single gene with three technical repeats per sample. Serial dilutions of 
plasmid controls with known molecule concentrations were used as a positive control and to 
generate standard curves for the PCR. Expression of target genes were normalized using 
36B4 (large ribosomal protein P0, RPLP0) as reference gene.  
Statistical analysis 
Data is presented as the mean of the samples and standard deviation as standard error of 
the mean (SEM). Statistical analysis was performed using the SigmaPlot 11.0 software 
(Systat Software Inc.) using one-way ANOVA analysis with a p-value < 0.05 (*), p<0.01 (**) 
and p<0.001 (***) considered statistically significant.   
 
Results 
Confirmatory Tests (MSC profile & delivery to brain) 
Prior to transplantation, MSCs were characterized by flow cytometry for MSC-specific 
marker expression and differentiation potential. Mouse-derived MSC showed positive 
expression for typical MSC markers CD44 and CD90 and negative expression for CD11b 
and CD45 as well as their ability to differentiate into osteoblasts, adipocytes and 
chondrocytes (data not shown). Up to 28 days after transplantation, GFP+-MSC were 
observed in hippocampus and cortex (Fig. 1 + Suppl.4). In addition to the MSC found in the 
brain, MSC were observed in bone marrow, lung and liver (manuscript in preparation). GFP+ 
MSC were found mainly around Aß plaques and seemed to be integrated into the corona of 
resident microglia surrounding these plaques. We did not observe transplant-related acute 
toxicity or adverse events. 
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Amyloid content  
We found no transplant-related changes in total amyloid-β content as measured by 
thioflavin-S staining of plaques at different sizes. However, we did observe changes in the 
pyroglutamate-beta amyloid (pE3-Aβ) sub-component of amyloid β plaques at day 28 (Fig.2, 
3). When pE3-Aβ plaques are categorized as small (<50µm), medium (50-100µm) and large 
(>100µm) as described by Kim et al. (7), we found a treatment-related increase in the 
number of small size plaques, but decrease in medium size plaques in the hippocampus on 
day 28 (Fig. 2C). No changes were observed in the cortex on day 28 (Fig.2B) and on day 7 
(Fig. 3A, left). 
Histology 
The following observations were made in histological analysis: Transplanted MSC (derived 
from GFP-transgenic mice) were found in and around amyloid plaques (Fig. 1 + Suppl. Fig 
5). A lower amount of pE3-Aβ was found within vessels of the MSC-treated group compared 
to controls (Fig. 3B). In addition, we observed pE3-Aβ accumulation in large astrocytes with 
processes (Fig. 3C). These cells were mainly seen around amyloid plaques and a reduction 
in the presence of these processes-bearing astrocytes was observed in the MSC-treated 
group compared to controls. We observed in the histological analysis variability between the 
different animals transplanted with MSC and controls indicating that even when all mice 
were close in age they behave independently.  
MSC transplantation effect on microglia  
It is known that MSC exert anti-inflammatory effects. We therefore examined whether 
APP/PS1 mice receiving MSC transplants showed a reduced microglia activation measured 
by microglia size, represented by Iba-1 covered area. Quantitative analysis showed that the 
total area occupied by Iba-1 positive microglia was significantly decreased in hippocampus 
and cortex of mice treated with MSC compared to NaCl at day 28 (Fig.4D). No significant 
differences were observed by day 7 in the hippocampus but were seen in the cortex (Suppl. 
Fig.3D). Microglia numbers were significantly reduced in the cortex but not in the 
hippocampus of the MSC-treated group compared to controls after 28 days (Fig.4B). No 
significant change was observed after 7 days (Suppl. Fig.3B).  
We observed that in mice receiving MSC that microglia were more regularly distributed in 
comparison to the more clustered distribution in the control group (Fig.4A&C; Suppl. Fig.3A 
& 3D). In addition, morphological changes were observed after transplantation. In MSC-
treated mice, microglia were more ramified with more processes per cell (Fig. 4C inserts).  
MSC transplantation effect on astrocytes 
In addition to microglia we wanted to examine whether transplanted MSC exert an effect on 
astrocyte activation. The analysis revealed changes in astrocytes distribution/area after 
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treatment with MSC compared to NaCl controls. We saw a reduction of GFAP covered area 
after 7 days, which was somewhat reduced by day 28 (Suppl. Fig.4).   
MSC effect on gene expression: inflammation, neurogenesis, chemotaxis    
Inflammation: Expression of TNF-α was reduced in the cortex and hippocampus of the 
transplant group compared to controls. IL-6 was reduced in the hippocampus only and no 
effect was found for IL-10 and IFN-γ (Fig 5&6). IL-6 expression was reduced in the 
hippocampus but not in the cortex. Expression level of PTGER2 was reduced in the cortex 
but elevated in the hippocampus of MSC transplanted animals compared to controls.  
Neurogenesis/Trophic factors: Expression of NGF was reduced in the cortex but not in the 
hippocampus of the transplant group compared to NaCl controls. No transplant-related 
changes were observed in either brain region for BDNF expression levels or for the 
angiogenesis gene VEGF-A (Fig.6).   
Chemotaxis: Expression of MCP-1 was reduced in the cortex and hippocampus of the 
transplant group compared to NaCl controls. No changes were observed for CCR5 levels.  
 
Discussion 
The role of neuroinflammation in the pathological progression of AD has been widely 
discussed (22, 23) as well as the pro-inflammatory reaction of microglia triggered by Aβ. In 
the current study, we used the transgenic APP/PS1 mouse model where amyloid plaques 
appear around week six and a full Aβ pathology by 8 months (19). The age of the recipient 
animals used in this study ranged from 13 to 15 months. In comparison to other AD mouse 
models the APP/PS1 mouse strain shows a stronger microgliosis, mimicking human 
microglial activation observed in AD (19).  
Injection of MSC into the tail vein appeared safe and effective: the GFP+MSC could be 
observed around Aβ plaques and were seen to settle between the microglial cells. This 
clearly indicates the potential of MSC to migrate not just towards the brain but to sites of 
inflammation therein. Secondly, we demonstrated that one single treatment with systemically 
transplanted MSC leads to obvious changes in Aß pathology.  
Recently, a study showed in the APP Tg2576 mouse model that human adipose stem cells 
labeled with magnetic nanoparticles reached the site after 1 day (24). Another group 
reported survival of transplanted GFP+MSCs into a (PLP)-α-SYN mouse model of multiple 
system atrophy after 4 weeks of transplantation in substantia nigra and brainstem (25). Our 
experiments document the presence of the transplanted MSC in the brain parenchyma 
within 4 weeks of delivery. In contrast to the direct access to the brain via stereotactic 
injection, systemic delivery of MSC via tail vein injection appeared safe and effective. 
Transplanted GFP+MSC were observed around Aβ plaques and seemed to be integrated 
into the corona of microglia surrounding the Aß deposits, which clearly indicates the potential 
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of MSC to migrate not just towards the brain but in addition they are attracted to other sites 
of inflammation therein. This, on the other hand, reveals a putative involvement in neuro-
inflammatory processes.  
There are three other groups studying the use of MSCs in mice as a potential therapy set up 
for Alzheimer’s (17, 26-29) however, most of these studies used either intracranial 
transplantation of MSCs or used human MSCs. They also showed a reduction of amyloid 
plaques after day 7 (28). The effect was no longer observed after 28 days indicating a short 
term effect of transplanted MSCs independent of the transplantation method. However, 
previous studies have accomplished amyloid plaque reduction through either multiple rounds 
of MSC transplantation or higher concentration of MSCs (8, 16, 17, 30-32). Systemic MSC 
transplantation has only been tested in very young AD mice (4 months) when the mice had 
not fully developed the Alzheimer pathology (31). Another study investigating systemic MSC 
transplantation did this for 6.5 months every 2 weeks for 2 months following monthly 
applications starting at age of 7 months (30, 31). In none of the publications was a single 
application of MSCs tested to demonstrate the efficiency.  
AD is characterized by the presence of increased levels of pro-inflammatory cytokines (33) 
mainly produced by aged microglia and astrocytes (34). Here we sought to explore the effect 
of MSC transplantation on general expression levels of genes related to inflammation, 
neurogenesis and chemotaxis.    
The fact that at each time point analysed some factors showed no transplant-related 
changes in gene expression, inflammation (IL-10, IFNγ), neurogenesis (VEGF-A, BDNF), 
chemotaxis (CCR5) indicates clearly that the effects of MSCs are not ubiquitous or 
necessarily on a broad spectrum and require a differentiated analysis.     
Yet in other respects, effects were found at each time point observed. Most notably in the 
neuroinflammation group, we observed a transplant-related reduction of TNF-α gene 
expression which is known to have a prominent role in AD disease progression maybe even 
initiating pathological changes (35, 36). The increasing expression of TNF-α in the cortex 
was shown in a triple transgenic AD mouse model at early pre-pathological time points, 
correlating with enhanced activation of microglia (37). In this mouse model, inflammatory 
changes also correlate with cognitive deficits and synaptic dysfunction (38, 39) and 
overexpression of TNF-α made a major contribution to neuronal death (40) whereas 
inhibition of TNF-α in an AD mouse model resulted in lower amyloid beta levels and 
cognitive impairment (41). In line with our findings, Kim et al. 2013 could also show down-
regulation of TNF-α up to 12 weeks after intravenous administration of human amniotic 
(placenta derived) stem cells in an APPswe (Tg2576) Alzheimer mouse model (7), others 
have demonstrated similar effects after intracranial application of MSCs (17, 42, 43). Less 
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pronounced than for TNF-α, expression levels of IL-6, another pro-inflammatory cytokine, 
was also reduced in the hippocampus but not in the cortex.  
In the neurogenesis group, we found MSC transplantation associated with a reduction in 
NGF expression. Perhaps surprisingly this could be construed as having a potential 
therapeutic benefit. While NGF supports survival, regulation and differentiation of neurons 
and neuronal stem cells (44), it is also associated with disturbed neurogenesis in AD (45-
47). High NGF levels result in impaired neocortical choline acetyl transferase (ChAT) activity 
which is linked to dementia and might be correlated with the memory loss observed in AD 
(48, 49). A reduction in NGF correlates with changes in microglial morphology and 
distribution. It is known that reactive microglia encourage pro-NGF expression resulting in 
detrimental effects (50).  
Since we analysed the NGF expression on mRNA level, we did not distinguish between pro-
NGF and mature NGF. Pro-NGF is elevated in AD patients (44) and is normally produced by 
microglia. The pro-NGF in AD is impaired (51) and subsequently induces apoptosis in 
neurons. Hence, the reduction on the expression level of NGF in this study could be 
beneficial in regard to a lower level of proNGF.  
The most direct indication of the complexity of MSC immune-modulatory effects is 
exemplified by our findings for prostaglandin E2 receptor (PTGER2), a pro-inflammatory 
factor, highly elevated in AD patients and implicated in AD progression (52, 53). PTGER2 
can be neurotoxic (54), but on the other hand PTGER2 signalling is implicated for its 
potential role in long-term synaptic plasticity and cognitive function (55). The observed MSC-
related decreased expression of PTGER2 in the cortex while increased in the hippocampus 
requires further study.  
During AD, MCP-1 expression is increased, attracting monocytes and microglia which 
account for pathological gliosis in AD (56). Here we show that transplanted MSCs are able to 
down-regulate MCP-1 levels – and a corresponding reduction in microglial numbers at least 
in the hippocampus was observed. Others in this field have observed a transplant-related 
increase in microglial levels (57) or no change over time (7). 
While the number of microglia may not be a good indicator of potential therapeutic action, 
changes in activation status might be more significant. Microglia exist in many different 
activation states (58). Aggregated Aβ is known to induce microglial activation (59). In this 
context, we find a transplant-associated reduction in large-sized microglia which are deemed 
indicative of an activated state (60). Such an effect was also found by Kim et al. (31) 
following systemic injection of placenta derived hMSC into APPswe (Tg2576) AD mice. The 
group observed an initial increase in microglial size, later followed by a size reduction, 
indicating that any studies into the immune-modulatory and anti-inflammatory dynamics of 
transplanted MSC are very time point dependent. This is also demonstrated by our 
observations shown in the supplementary data. Ultimately, to use the immune modulatory 
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properties of MSCs for therapeutic purposes, the long-term effects on AD disease 
progression will need to be investigated as well as the benefits of follow-up transplantation of 
MSC. 
In summary, these findings support the hypothesis that MSC-transplants may affect AD 
pathology via an immune modulatory function that includes an effect on microglia cells.  
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Legends 
Figure 1. Migration of transplanted mesenchymal stem cells into the brain of APP/PS1 
mice. Intravenously transplanted eGFP+-MSCs were able to migrate into the brain 
parenchyma. eGFP+-MSCs (Anti-GFP; green) were found associated with activated 
microglia (Iba-1; red) but not showing IBA-1 immunoreactivity. Lower row, right picture: 
Overlay with orthoview based on stack analysis, supplemented by nuclei staining (DAPI, 
blue). 
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Figure 2. Transplanted mesenchymal stem cells alleviate pE3-Aβ plaque size in brains 
of APP/PS1 mice (A) Brain sections from control animals and MSC treated AD mice stained 
for anti-pE3-Aβ (control group, d7, d28). Cortex and hippocampus areas were analysed and 
the level of pE3-Aβ plaque size for the cortex (B) and hippocampus (C) areas was quantified 
at day 28.Small, middle and large pE3-Aß plaques are shown exemplarily below. Data is 
representative as mean ± SEM for BM-MSC (n=4) and NaCl (n=5). Statistical significances 
are represented as *p<0.05, ** p<0.01 and *** p<0.001. 
 
Figure 3. pE3-Aβ plaque size at day 7 and distribution and presence of pE3-Aβon 
vessels and in astrocytes after MSC transplantation. (A) Analysis of pE3-Aβ plaque size 
for the cortex and hippocampus at day 7 after transplantation. Presence of pE3-Aβ in 
vessels (B) and astrocytes (C) shown after transplantation. Red arrows indicate the 
presence of pE3-Aβ in veins and pE3-Aβ in astrocytes and black arrows show the amyloid 
plaques. Data is representative as mean ± SEM for BM-MSC (n=3) and NaCl (n=3). 
 
Figure 4. BM-MSC trigger activation of microglia cells in cortex and hippocampus in 
the brain of APP/PS1 mice. (A) Brain sections stained for Iba-1 in APP/PS1 mice 
transplanted with MSC or NaCl. (B) Quantitative stereological analysis for microglia (Iba-1) 
number in the cortex and hippocampus of APP/PS1 mice transplanted with MSC or NaCl. 
(C) Representative pictures of microglia distribution and morphology for cortex and 
hippocampus area. (D) Quantitative analysis of microglia activation on the basis of microglia 
size. Data is representative as mean ± SEM for BM-MSC (n=4) and NaCl (n=5). Statistical 
significances are represented as *p<0.05, ** p<0.01 and *** p<0.001. 
 
Figure 5. Treatment with BM-MSC resulted in changed levels in growth factors, 
inflammation and migration markers after transplantation in the cortex of APP/PS1 
mice. mRNA expression of chemoattractant MCP-1& CCR5, growth factors NGF& BDNF 
and inflammation markers PTGER2, TGF-β, TNF-α, and IL-6 in cortex of APP/PS1 which 
received either BM-MSC (n=3) or NaCl (n=5). Most markers showed a clear decrease in 
MSC-treated animals compared to the control group; however IL-6 and BDNF revealed an 
increase. Values were normalized to 36B4 level. Data is represented as mean ± SD. 
Statistical significances are represented as *p<0.05, ** p<0.01 and *** p<0.001. 
 
Figure 6. BM-MSC resulted in changed levels of inflammation markers after 
transplantation in the hippocampus of APP/PS1 mice. mRNA expression of 
chemoattractant MCP-1 & CCR5, growth factors NGF & BDNF & VEGF-A and inflammation 
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markers PTGER2, TNF-α, IFN-γ, IL-10 and IL-6 in hippocampus of APP/PS1 which received 
either BM-MSC (n=3) or NaCl (n=5). Most markers showed a clear down-regulation in MSC-
treated animals compared to the control group; however PTGER, IL-10 and CCR5 revealed 
an increase. Values were normalized to 36B4 level. Data is represented as mean ± SD. 
Statistical significances are represented as *p<0.05, ** p<0.01 and *** p<0.001. 
 
Supplementary Figure 1. Stereological analysis of pE3-Aß plaques in MSC-treated 
APP/PS1 mice vs. controls (NaCl). pE3-Aß plaque numbers in the cortex and 
hippocampus of BM-MSC treated APP/PS1 mice compared to the control group at day 7 (A) 
for BM-MSC (n=3) and NaCl (n=3) and day 28 (B) for BM-MSC (n=4) and NaCl (n=5) post-
transplantation. Data is representative as mean ± SEM. 
 
Supplementary Figure 2. Analysis of Thioflavin S covered area in MSC-treated 
APP/PS1 mice vs. controls (NaCl). Thioflavin S covered area was analysed on day 7 and 
day 28 after MSC transplantation. Data is representative as mean ± SEM for BM-MSC (n=3 
(d7) and n=4 (d28)) and NaCl (n=3 (d7) and n=5 (d28)). Statistical significances are 
represented as *p<0.05, ** p<0.01 and *** p<0.001 
 
Supplementary Figure 3. Effect of MSC transplantation on microglia activation in 
cortex and hippocampus in the brain of APP/PS1 mice at day 7. (A) Microglia 
distribution in MSC-treated APP/PS1 mice vs. control (NaCl). (B) Stereological analysis of 
microglia numbers in the cortex and hippocampus at day 7. (C) Representative distribution 
and morphology of Iba-1 positive cells in the cortex and hippocampus for MSC-treated 
APP/PS1 mice vs. controls (NaCl) at day 7. (D) Analysis of activated microglia by 
measurement of IBA-1 covered area for MSC-treated APP/PS1 mice vs. controls (NaCl) at 
day 7. Data is shown representative as mean ± SEM for BM-MSC (n=3) and NaCl (n=3). 
 
Supplementary Figure 4. Effect of MSC transplantation on astrocyte activation in 
cortex and hippocampus in the brain of APP/PS1 mice at day 7. Analysis of activated 
astrocytes by measuring GFAP-covered area for the cortex (A) and hippocampus (B) after 
MSC transplantation vs. controls (NaCl). Data is representative as mean ± SEM for BM-MSC 
(n=3-4) and NaCl (n=8). 
 
Supplementary Figure 5. Presence of transplanted GFP-MSC around amyloid plaques. 
Intravenously transplanted eGFP+-MSCs were able to migrate into the brain parenchyma. 
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eGFP+-MSCs (Anti-GFP; green) were found associated with activated microglia (Iba-1; red) 
but not showing IBA-1 immunoreactivity. Nuclei were stained with DAPI (blue). Pictures were 
taken with a Zeiss confocal microscope at 40x magnification. 
 
Supplementary Figure 6. MSC characterisation. In vitro differentiation of BM-MSC under 
adipogenic (A), osteogenic (B) or chondrogenic (C) conditions. Differentiation was verified by 
qualitative analysis: Adipogenesis was shown by staining lipid vesicles with Oil Red-O (A), 
osteogenesis was shown by staining alkaline phosphatase with Fast Red (B) and 
chondrogenesis was shown by staining sulphated proteoglycans typical for extracellular 
matrix composition with Alcian Blue under acidic conditions. 
 
Supplementary Figure 7. MSC characterisation. BM-MSC were analysed using FACS 
staining. MSC were stained with DIO and DIL (positive controls for FL1 and FL2) and IgG as 
negative control. MSC were found to be negative for CD11b and CD45 and positive for 
CD44, CD90, CD105 and CD133.  
 
Table 1. Primer sequences used for qPCR 
Name Gene Sense primer [5‘-3‘] Antisense primer [5‘-3‘] NCBI 
accessio
n number 
36B4 ribosomal 
protein large 
P0 RPLP0 
CCGTGTGAGGTCACT
GTGCCAGCTC 
GCCCAAAGCCTGGAA
GAAGGAGGTC 
NM_0074
75.5 
IL-6 interleukin 6 CCAGTTGCCTTCTTGG
GACTGATG 
CCGGACTTGTGAAGTA
GGGAAGGC 
NM_0311
68.1 
TNF-α tumor 
necrosis 
factor 
GACAGCAAGGGACTA
GCCAGGAGGG 
GGGAGTGCCTCTTCT
GCCAGTTCC 
NM_0136
93.2 
MCP-1 transcription 
regulatory 
protein MCP-
1 (POU 1) 
GCAGTAATCCTCACCA
GCCCAACGC 
GATCCCGTCCTCATCC
AGACTTGG 
 
L13763.1 
PTGE
R2 
Prostaglandi
n E2 receptor 
subtype 2 
CGGCACGGGAGGACT
GCATACCTTC 
GCAGCGGCTTCTTCTG
CTCCGACG 
NM_0089
64.4 
VEGF-
A 
vascular 
endothelial 
growth factor 
A 
CCGGAGGGCGAGACT
CCG 
GTGGGTGTGTCTACA
GGAATCCCAG 
NM_0010
25250.3 
NGF nerve growth 
factor 
GGCTGGATGGCATGC
TGGACCC 
GTACGGTTCTGCCTGT
ACGCCGATC 
NM_0136
09.2 
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